Keywords: astrazeneca, atacand, shows, superiority, over, merck, cozaar
AstraZeneca's Atacand shows superiority over Merck's Cozaar
Article | 19 August 1999
- AstraZeneca's angiotensin receptor blocker Atacand (candesartan),recently launched in the USA, provided a significantly greater reduction in diastolic blood pressure ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
